Showing results (451-460 of 2,338) with videos related to

Sort By:
Pageof 234
Clinical Lung Cancer|March 25, 2015
Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung AdenocarcinomaCheng Lin, Xiong Chen, Meifang Li, et al.
Clinical Lung Cancer|July 30, 2020
Imaging in Therapy Response Assessment and Surveillance of Lung Cancer: Evidenced-based Review With Focus on the Utility of 18F-FDG PET/CTSara Sheikhbahaei, Franco Verde, Russell K Hales, et al.
Clinical Lung Cancer|July 31, 2020
Randomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901Arkadiusz Z Dudek, Xiaofei Wang, Lin Gu, et al.
Clinical Lung Cancer|August 5, 2020
EGFR Tyrosine Kinase Inhibitor (TKI) Combined With Concurrent or Sequential Chemotherapy for Patients With Advanced Lung Cancer and Gradual Progression After First-Line EGFR-TKI Therapy: A Randomized Controlled StudyQing Chang, Jianlin Xu, Huiping Qiang, et al.
Clinical Lung Cancer|January 15, 2014
Rationale and design of MILES-3 and MILES-4 studies: two randomized phase 3 trials comparing single-agent chemotherapy versus cisplatin-based doublets in elderly patients with advanced non--small-cell lung cancerCesare Gridelli, Antonio Rossi, Massimo Di Maio, et al.
Clinical Lung Cancer|August 17, 2022
Germline Testing of Patients With Non-small Cell Lung Cancers Demonstrating Incidentally Uncovered BRCA2 Apparent Pathogenic Germline VariantsSteven Sorscher
Clinical Lung Cancer|August 12, 2022
Oncogene Overlap Analysis of Circulating Cell-free Tumor DNA to Explore the Appropriate Criteria for Defining MET Copy Number-Driven Lung CancerDavid C C Tsui, Leylah M Drusbosky, Sara Wienke, et al.
Clinical Lung Cancer|August 30, 2021
Safety and Clinical Activity of Atezolizumab Plus Ipilimumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Results From a Phase 1b TrialDeborah J Wong, Todd M Bauer, Michael S Gordon, et al.
Clinical Lung Cancer|August 9, 2022
Association Between Survival and Very High Versus High PD-L1 Expression in Patients Receiving Pembrolizumab as First-line Treatment for Advanced Non-Small Cell Lung CancerMohsin Shah, Melina E Marmarelis, Ronac Mamtani, et al.
Clinical Lung Cancer|August 21, 2022
Race is a Risk Factor for the Deferral of Resection and Radiation for Early-Stage Lung CancerCharles Y Huang, Shale Mack, Tyler R Grenda, et al.
Pageof 234